
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Thirty Years of Pharm Exec
about 15 years ago
Y. K Hamied : Changing the Dialogueabout 15 years ago
Fred Frank: Fortune and the Financierabout 15 years ago
Marck McLellan: An 'A' for Advancing Expectationsabout 15 years ago
Inside the Mind of the CEO: Steve Collisabout 15 years ago
Atsushi Nagahisa: Creating Customer Valueabout 15 years ago
Physicians: Still the Vital Connection in Medicineabout 15 years ago
Henry Waxman: "Representing" Healthcare to the Fullestabout 15 years ago
IP: Securing a Global Consensus—Can Industry Do It Again?about 15 years ago
In Establishing the Evidence Base, He Made Science Countabout 15 years ago
Jane Henney: Lessons from the FDA Front Line




